| Dr William Victor Griffith, MD | |
|
735 Mcmillan Rd, Clemson, SC 29634-4054 | |
| (864) 656-0692 | |
| (864) 656-1619 |
| Full Name | Dr William Victor Griffith |
|---|---|
| Gender | Male |
| Speciality | General Practice |
| Location | 735 Mcmillan Rd, Clemson, South Carolina |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1356469431 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208D00000X | General Practice | 9511 (South Carolina) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Dr William Victor Griffith, MD 735 Mcmillan Rd, Clemson, SC 29634-4054 Ph: (864) 656-0692 | Dr William Victor Griffith, MD 735 Mcmillan Rd, Clemson, SC 29634-4054 Ph: (864) 656-0692 |
News Archive
A sun protection intervention program that encouraged fourth-graders to wear hats outdoors as a skin cancer prevention measure significantly increased hat use at school, a study by researchers at the University of South Florida College of Medicine found. The program, however, had no effect on self-reported hat use at home or on measures of skin pigmentation.
Pateamine A (PatA), a natural product first isolated from marine sponges, has attracted considerable attention as a potential anti-cancer agent, and now a new activity has been found for it, which may reveal yet another anti-cancer mechanism. That's the assessment of Daniel Romo, a Texas A&M chemistry professor, and his colleagues at Johns Hopkins University who are pioneers in research involving this novel marine natural product.
A new study published by The University of Western Ontario reveals that couples who share the responsibility for paid and unpaid work report higher average measures of happiness and life satisfaction than those in other family models.
Incyte Corporation announces updated data from its ongoing Phase 2 FIGHT-202 trial evaluating pemigatinib (INCB54828), its selective fibroblast growth factor receptor (FGFR) inhibitor, in patients with advanced/metastatic or surgically unresectable cholangiocarcinoma (bile duct cancer) who failed at least one previous treatment.
When a long, black bus bearing the logo of drugmaker AbbVie rolls through Washington state next year, it will promote a new effort to eradicate hepatitis C infections.
› Verified 2 days ago
Dr. Byron Blasdell Harder, M.D. General Practice Medicare: Not Enrolled in Medicare Practice Location: 344054 Mcmillan, Clemson University, Clemson, SC 29634 Phone: 864-656-2233 Fax: 864-656-0760 |